Breast Cancer Survival is Linked to Muscle Mass
In a recent study, scientists found that breast cancer patients with decreased muscle mass may have a significantly higher risk of death compared to patients without it. This study, titled “Association of Muscle and Adiposity Measured by Computed Tomography with Survival in Patients With Nonmetastatic Breast Cancer” was published in JAMA Oncology on April 5, 2018*. They examined 3,241 women from Kaiser Permanente of Northern California and Dana Farber Cancer Institute of Harvard Medical School between January 2000 and December 2013. Very importantly, these patients did not have metastatic cancer but rather were diagnosed with stage II or stage III breast cancer that are potentially curable. According to their results, muscle characteristics appear to be important predictors of survival for those who have breast cancer. Patients who had decreased muscle mass were 41 percent less likely to have survived than those who did not. Patients with the highest amount of body fat were also linked to an increased mortality risk. Patients who had both were 89 percent more likely to have died. At Nutronco we have been emphasizing the utmost importance of nutrition and especially protein intake to help rebuild and maintain muscle mass in cancer patients. This is the largest study to date of patients with nonmetastatic breast cancer, and it demonstrated that decreased muscle mass (sarcopenia) is underrecognized, highly prevalent, and is associated with a significant increased risk of death. The authors of the study concluded that we should consider interventions to improve muscle mass such as protein supplementation. Our PowerOnco supplement provides high quality pure protein with high amount of branched chain amino acids, especially leucine, that has been shown to be the most powerful booster of muscle mass.
*Caan BJ, Cespedes Feliciano EM, Prado CM et al. Association of Muscle and Adiposity Measured by Computed Tomography with Survival in Patients With Nonmetastatic Breast Cancer. JAMA Oncol 2018 Apr 5.
Peter Acs, MD, PhD – Medical Oncologist
Updated 7:00 PM ET, Thursday June 21, 2018
Leave a ReplyWant to join the discussion?
Feel free to contribute!